Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease.
Iago Rodriguez-LagoJavier Del HoyoAlexandre Pérez-GirbésAlejandro Garrido-MarínMaría José CasanovaMaría ChaparroAgnès Fernández-ClotetJesús Castro-PoceiroMaría José GarcíaSara SánchezRocío Ferreiro-IglesiasIria BastónMarta PiquerasLola Esteba I Bech de CaredaRaquel MenaCristina SuárezJoaquín Poza CordónAlicia López-GarcíaLucía MárquezMaría Teresa Arroyo VillarinoErika AlfambraMónica SierraNoelia CanoPedro Delgado-GuillenaVíctor Jair Morales-AlvaradoJuan Carlos AparicioIván GuerraCarolina AullóOlga MerinoLaura ArranzMaría Araceli HidalgoJordina LlaóRocío PlazaGema MolinaPaola TorresPablo Pérez-GalindoMaría Giselle RomeroClaudia Herrera-deGuiseEdisa ArmestoFrancisco MesoneroSantiago Frago-LarramonaJosé Manuel BenítezMarta CalvoMaría Del Carmen López MartínAinara ElorzaAlejandro LarenaElena PeñaMaría Del Carmen Rodríguez-GrauJaime de Miguel-CriadoBelén BotellaJosé Antonio OlmosLaura LópezUrko AguirreFrancisco Javier García-Alonsonull nullPublished in: United European gastroenterology journal (2020)
Anti-TNF agents are effective in approximately a quarter of patients with Crohn's disease and symptomatic intestinal strictures, and 68% of patients are free of surgery after a median of 40 months of follow-up. Early treatment and some potential predictors of response were associated with treatment success in this setting.